HICKY, aiming for innovative treatment of central sleep apnea to improve prognosis for heart failure patients, raises funds from Tokyo Wellness Impact Fund and CJS No. 2 Fund
NQ Score
42/100
N1 Content Completeness
4
AI Summary (NQ-processed)
HICKY Inc., a company developing treatment devices for central sleep apnea to improve the prognosis of heart failure, has raised funds from the Tokyo Wellness Impact Fund and CJS No. 2 Fund. This funding will accelerate the development of next-generation treatment devices and fully launch initiatives for clinical trials and commercialization.